Verismo Therapeutics, a Philadelphia-based clinical-stage CAR-T company, Penn spinout, and pioneer of the novel anti tumor KIR-CAR platform technology, announced that Dr Mala Talekar has joined the company as vice president of Clinical Development.

On the appointment Mala said, "I am excited to be a part of the Verismo team and to continue developing and delivering cutting-edge treatments to patients.”

"We are excited to have Mala join our team," said Dr Bryan Kim, Verismo's chief executive officer. "As a veteran physician in both cell therapy and immuno-oncology with experience in the clinic and industry, she will be a valuable asset as we continue to bring innovative treatments to patients."